Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

A report released yesterday underlines the danger of Trasylol (aprotinin), which was used for years to limit bleeding during surgery. Trasylol was taken off the market last year after U.S. tests indicated the drug posed a significantly higher risk of death as opposed to other anti-bleeding drugs.

The new study, as reported by Forbes.com, includes an examination of Trasylol use in 49 randomized clinical trials, and also includes new information from the Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study, published earlier this year. The findings of the new study, which was conducted by Canadian and Australian reserachers, will be published in the Jan. 20 issue of the Canadian Medical Association Journal.

Read the rest of this entry »

A conclusive study of Bayer AG’s aprotinin injection Trasylol uncovered a grim fact: one out of every 50 Trasylol recipients dies. The study was conducted in Canada and involved monitoring the health of 2,331 high-risk heart patients.

Read the rest of this entry »

The FDA announced today that Bayer Pharmaceuticals Corp. will begin removing all remaining supplies of the drug Trasylol (aprotinin) from warehouses and other medical stock. The decision comes following the preliminary results of a test that showed the drug greatly increased the risk of death. Trasylol is administered to patients undergoing heart surgery to slow bleeding and reduce or eliminate the need for blood transfusions.

Read the rest of this entry »